Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
AMEX:CRMD's Cash-to-Debt is ranked higher than
82% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. AMEX:CRMD: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
AMEX:CRMD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.73
AMEX:CRMD's Equity-to-Asset is ranked higher than
58% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AMEX:CRMD: 0.73 )
Ranked among companies with meaningful Equity-to-Asset only.
AMEX:CRMD' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.36  Med: 0.81 Max: 0.95
Current: 0.73
-1.36
0.95
Interest Coverage No Debt
AMEX:CRMD's Interest Coverage is ranked lower than
99.99% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AMEX:CRMD: No Debt )
Ranked among companies with meaningful Interest Coverage only.
AMEX:CRMD' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: -9.25
Beneish M-Score: 0.13
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -8838.89
AMEX:CRMD's Operating Margin % is ranked lower than
93% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. AMEX:CRMD: -8838.89 )
Ranked among companies with meaningful Operating Margin % only.
AMEX:CRMD' s Operating Margin % Range Over the Past 10 Years
Min: -245750  Med: -9492.25 Max: -4710.05
Current: -8838.89
-245750
-4710.05
Net Margin % -8265.50
AMEX:CRMD's Net Margin % is ranked lower than
93% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. AMEX:CRMD: -8265.50 )
Ranked among companies with meaningful Net Margin % only.
AMEX:CRMD' s Net Margin % Range Over the Past 10 Years
Min: -456650  Med: -10911.74 Max: -8660.95
Current: -8265.5
-456650
-8660.95
ROE % -147.12
AMEX:CRMD's ROE % is ranked lower than
83% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. AMEX:CRMD: -147.12 )
Ranked among companies with meaningful ROE % only.
AMEX:CRMD' s ROE % Range Over the Past 10 Years
Min: -678.23  Med: -126.09 Max: -95.1
Current: -147.12
-678.23
-95.1
ROA % -119.73
AMEX:CRMD's ROA % is ranked lower than
87% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. AMEX:CRMD: -119.73 )
Ranked among companies with meaningful ROA % only.
AMEX:CRMD' s ROA % Range Over the Past 10 Years
Min: -507.14  Med: -189.63 Max: -83.53
Current: -119.73
-507.14
-83.53
ROC (Joel Greenblatt) % -47429.53
AMEX:CRMD's ROC (Joel Greenblatt) % is ranked lower than
92% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. AMEX:CRMD: -47429.53 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AMEX:CRMD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -53119.48  Med: -39827.19 Max: -25220.83
Current: -47429.53
-53119.48
-25220.83
3-Year EBITDA Growth Rate 5.20
AMEX:CRMD's 3-Year EBITDA Growth Rate is ranked higher than
54% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. AMEX:CRMD: 5.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AMEX:CRMD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -66.6  Med: 5.2 Max: 30.3
Current: 5.2
-66.6
30.3
3-Year EPS without NRI Growth Rate -2.00
AMEX:CRMD's 3-Year EPS without NRI Growth Rate is ranked higher than
50% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. AMEX:CRMD: -2.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AMEX:CRMD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -68.4  Med: -2 Max: 24.6
Current: -2
-68.4
24.6
GuruFocus has detected 2 Warning Signs with Cormedix Inc $AMEX:CRMD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AMEX:CRMD's 30-Y Financials

Financials (Next Earnings Date: 2017-11-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

CRMD Guru Trades in Q3 2016

Paul Singer 1,500,200 sh (unchged)
» More
Q4 2016

CRMD Guru Trades in Q4 2016

Paul Singer 1,500,200 sh (unchged)
» More
Q1 2017

CRMD Guru Trades in Q1 2017

Paul Singer 1,500,200 sh (unchged)
» More
Q2 2017

CRMD Guru Trades in Q2 2017

Paul Singer 4,166,868 sh (+177.75%)
» More
» Details

Insider Trades

Latest Guru Trades with AMEX:CRMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:TSXV:DMA, NAS:PTIE, OTCPK:EMIS, NAS:CLRB, NAS:VICL, OTCPK:MRNA, AMEX:BPMX, AMEX:IBIO, NAS:OCRX, NAS:DFFN, NAS:JAGX, NAS:AVIR, NAS:CAPR, OTCPK:SNBP, OTCPK:CELZ, NAS:HTBX, OTCPK:GBLX, NAS:PRTO, NAS:XBIO, OTCPK:PRTX » details
Traded in other countries:19K.Germany,
Headquarter Location:USA
Cormedix Inc is a commercial-stage biopharmaceutical company. It focuses on development and commercializing prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases.

Cormedix Inc was organized as a Delaware corporation on July 28, 2006 under the name Picton Holding Company, Inc. and changed it to CorMedix Inc. on January 18, 2007. The Company develops and seeks to commercialize products for the treatment of cardiac, renal and infectious diseases. Its principal product under development includes CRMD003, an antimicrobial/anticoagulant solution applied in the prevention of catheter related bloodstream infections and maintenance of catheter patency in central venous catheters used for vascular access in hemodialysis patients. Its products also include CRMD004, a pressure sensitive gel that is in pre-clinical Phase.

Ratios

vs
industry
vs
history
PB Ratio 1.81
CRMD's PB Ratio is ranked higher than
83% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. CRMD: 1.81 )
Ranked among companies with meaningful PB Ratio only.
CRMD' s PB Ratio Range Over the Past 10 Years
Min: 1.3  Med: 3.49 Max: 31.85
Current: 1.81
1.3
31.85
PS Ratio 58.75
CRMD's PS Ratio is ranked lower than
83% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. CRMD: 58.75 )
Ranked among companies with meaningful PS Ratio only.
CRMD' s PS Ratio Range Over the Past 10 Years
Min: 42.5  Med: 363.67 Max: 2810
Current: 58.75
42.5
2810
EV-to-EBIT -0.36
CRMD's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. CRMD: -0.36 )
Ranked among companies with meaningful EV-to-EBIT only.
CRMD' s EV-to-EBIT Range Over the Past 10 Years
Min: -22.6  Med: -2.1 Max: -0.1
Current: -0.36
-22.6
-0.1
EV-to-EBITDA -0.36
CRMD's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. CRMD: -0.36 )
Ranked among companies with meaningful EV-to-EBITDA only.
CRMD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -22.6  Med: -2.1 Max: -0.1
Current: -0.36
-22.6
-0.1
EV-to-Revenue 29.80
CRMD's EV-to-Revenue is ranked lower than
73% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. CRMD: 29.80 )
Ranked among companies with meaningful EV-to-Revenue only.
CRMD' s EV-to-Revenue Range Over the Past 10 Years
Min: -2.8  Med: 287.35 Max: 3210.5
Current: 29.8
-2.8
3210.5
Current Ratio 3.64
CRMD's Current Ratio is ranked lower than
52% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. CRMD: 3.64 )
Ranked among companies with meaningful Current Ratio only.
CRMD' s Current Ratio Range Over the Past 10 Years
Min: 0.1  Med: 4.57 Max: 20.26
Current: 3.64
0.1
20.26
Quick Ratio 3.59
CRMD's Quick Ratio is ranked higher than
50% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. CRMD: 3.59 )
Ranked among companies with meaningful Quick Ratio only.
CRMD' s Quick Ratio Range Over the Past 10 Years
Min: 0.1  Med: 4.35 Max: 19.89
Current: 3.59
0.1
19.89
Days Inventory 257.77
CRMD's Days Inventory is ranked lower than
58% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. CRMD: 257.77 )
Ranked among companies with meaningful Days Inventory only.
CRMD' s Days Inventory Range Over the Past 10 Years
Min: 72.28  Med: 246.36 Max: 480.56
Current: 257.77
72.28
480.56
Days Sales Outstanding 164.36
CRMD's Days Sales Outstanding is ranked lower than
79% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. CRMD: 164.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRMD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 19.55  Med: 259.75 Max: 549.24
Current: 164.36
19.55
549.24
Days Payable 2.00
CRMD's Days Payable is ranked lower than
96% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. CRMD: 2.00 )
Ranked among companies with meaningful Days Payable only.
CRMD' s Days Payable Range Over the Past 10 Years
Min: 730.82  Med: 1667.28 Max: 1955.44
Current: 2
730.82
1955.44

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -34.50
CRMD's 3-Year Average Share Buyback Ratio is ranked lower than
81% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. CRMD: -34.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CRMD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -137  Med: -34.5 Max: -13.3
Current: -34.5
-137
-13.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.13
CRMD's Price-to-Net-Cash is ranked higher than
89% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. CRMD: 2.13 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CRMD' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.95  Med: 3.91 Max: 35.14
Current: 2.13
1.95
35.14
Price-to-Net-Current-Asset-Value 1.80
CRMD's Price-to-Net-Current-Asset-Value is ranked higher than
92% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. CRMD: 1.80 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CRMD' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.65  Med: 3.54 Max: 31.74
Current: 1.8
1.65
31.74
Price-to-Tangible-Book 1.81
CRMD's Price-to-Tangible-Book is ranked higher than
86% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. CRMD: 1.81 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CRMD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.66  Med: 3.54 Max: 31.24
Current: 1.81
1.66
31.24
Price-to-Median-PS-Value 0.16
CRMD's Price-to-Median-PS-Value is ranked higher than
91% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CRMD: 0.16 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CRMD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 1 Max: 6.97
Current: 0.16
0.15
6.97
Earnings Yield (Greenblatt) % -277.78
CRMD's Earnings Yield (Greenblatt) % is ranked lower than
96% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. CRMD: -277.78 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CRMD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -26203.2  Med: -48.3 Max: 2995.2
Current: -277.78
-26203.2
2995.2

More Statistics

Revenue (TTM) (Mil) $0.34
EPS (TTM) $ -0.68
Beta2.40
Short Percentage of Float5.21%
52-Week Range $0.32 - 3.26
Shares Outstanding (Mil)61.73

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1 5
EPS ($) -0.55 -0.28 -0.30
EPS without NRI ($) -0.55 -0.28 -0.30
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for AMEX:CRMD

Headlines

Articles On GuruFocus.com
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in CorMed Aug 07 2015 
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CorMedix, Inc. of Pendency of Clas Jul 16 2015 
Paul Singer's Latest Portfolio Increases and Reduction Mar 04 2015 
CorMedix Receives Approval From FDA to Initiate a Clinical Trial for Neutrolin in the US Oct 27 2014 
Weekly CFO Buys Highlight: CEP, JNS, CRMD, VAC, TICC Dec 26 2011 
Weekly CFO Buys Highlight: POL, ARAY, ZBB, CRMD, VRX Dec 19 2011 
CORMEDIX INC Reports Operating Results (10-Q) Nov 09 2010 

More From Other Websites
CorMedix Inc. to Present at The MicroCap Conference on October 5th in New York City at the Essex... Sep 21 2017
CorMedix Inc. to Present at the Anti-Infectives Rx Conference Sep 12 2017
CorMedix Inc. Presents Data Demonstrating Antimicrobial Activity of Taurolidine Against Potentially... Sep 07 2017
Are Options Traders Betting on a Big Move in CorMedix (CRMD) Stock? Sep 07 2017
CorMedix Inc. to Present at 2017 Rodman & Renshaw 19th Annual Global Investment Conference Sep 05 2017
ETFs with exposure to CorMedix, Inc. : August 31, 2017 Aug 31 2017
CorMedix Inc. Announces a Change to its Senior Leadership Aug 25 2017
CorMedix, Inc. :CRMD-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Aug 24 2017
CorMedix, Inc. Awarded NIH Grant to Develop Advanced Antimicrobial Hydrogels for the Treatment and... Aug 17 2017
Is the Options Market Predicting a Spike in CorMedix (CRMD) Stock? Aug 16 2017
CorMedix Inc. Reports Second Quarter Financial Results and Provides Business Update Aug 09 2017
Investor Network: CorMedix Inc. to Host Earnings Call Aug 09 2017
CorMedix Inc. Appoints Gary Gelbfish, M.D., to Board of Directors Aug 07 2017
CorMedix Inc. to Report Second Quarter 2017 Financial Results and Provide Business Update Aug 04 2017
CorMedix Inc. Provides Update on Neutrolin(R) Ongoing Phase 3 Clinical Trial Following Favorable FDA... Aug 02 2017
Implied Volatility Surging For CorMedix Inc (CRMD) Stock Options Jul 14 2017
CorMedix Inc. Provides Comprehensive Pipeline Update During Research and Development Day Jul 12 2017
CorMedix Inc. Appoints Mehmood Khan, M.D. and Steven Lefkowitz to its Board of Directors Jun 26 2017
Implied Volatility Surging for CorMedix (CRMD) Stock Options Jun 23 2017
ETFs with exposure to CorMedix, Inc. : June 16, 2017 Jun 16 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}